BRIEF published on 09/16/2026 at 08:05, 8 days 15 hours ago TME Pharma NV's strategy and financial commitment Biotechnology Partnerships Financial Strategy TME Pharma NOX-A12
PRESS RELEASE published on 09/16/2026 at 08:00, 8 days 15 hours ago TME PHARMA CEO MESSAGE TME Pharma CEO message emphasizes strategic approach, financial discipline, and long-term value creation for shareholders. Updates on NOX-A12, cost-reduction strategy, and future plans CEO Message Financial Discipline TME Pharma Strategic Approach NOX-A12
BRIEF published on 08/24/2026 at 08:10, 1 month ago TME Pharma Advances Toward Strategic Partnerships for Cancer Therapy Glioblastoma NOX-A12 Licensing Partnerships Biotech Market Trends CEO Share Transaction
PRESS RELEASE published on 08/24/2026 at 08:05, 1 month ago TME Pharma provides update on its activities TME Pharma provides update on its activities including final evaluation phase with potential partners for NOX-A12, with estimated peak sales potential of $1 billion, strategic decision framework, and scientific validation Clinical-stage Biotechnology License Agreement TME Pharma NOX-A12 Brain Cancer
BRIEF published on 10/30/2025 at 21:05, 10 months 25 days ago TME Pharma's Semi-Annual Report and Financial Restructuring Financial Results Biotechnology CEO Appointment Bond Issuance TME Pharma
PRESS RELEASE published on 10/30/2025 at 21:00, 10 months 25 days ago TME Pharma publishes its semi annual results and half-year report TME Pharma publishes semi annual results and half-year report showing cost reductions, new CEO, and fundraising activities. Focus on NOX-A12 and NOX-E36 assets Fundraising Cost Reductions TME Pharma NOX-A12 Semi Annual Results
PRESS RELEASE published on 09/01/2025 at 08:45, 1 year ago Inside Information: Other news releases TME Pharma completes August financing, with €500k cash received on August 28th, bringing cash position to €2.35M. Organization aims to attract financing for cancer and eye therapies Cash Position TME Pharma August Financing Cost-efficient Organization Novel Therapies
BRIEF published on 09/01/2025 at 08:45, 1 year ago TME Pharma successfully completes its August fundraising round Biotechnology Fundraising Treasury Cryptocurrencies Cancer
BRIEF published on 08/25/2025 at 08:05, 1 year ago TME Pharma Secures €500,000 through New Bond Issue Investment Strategy Cost Reduction Bond Issuance Financial Strategy Shareholder Commitments
PRESS RELEASE published on 08/25/2025 at 08:00, 1 year ago Inside Information / Other news releases TME Pharma to raise €500k through bond issue & receives new shareholding notice. CEO & Chairman also invest. Funds to boost financial position & support R&D projects & investment strategy Fundraising Shareholding CEO Bond Issue TME Pharma
Published on 09/24/2026 at 22:01, 1 hour 54 minutes ago Fermi Selects CBRE to Operate and Maintain Its First Data Center
Published on 09/24/2026 at 14:55, 9 hours ago Nextech3D.ai Surpasses $1 Million in New Customer Contract Value, Expands AI Software Portfolio with KATE and Grows Multi-Year Enterprise Agreements
Published on 09/24/2026 at 14:30, 9 hours 25 minutes ago Solitario Resources CEO to Present at the 38th Annual Mining Forum Americas 2026 Conference
Published on 09/24/2026 at 14:00, 9 hours 55 minutes ago Horizon Aircraft to Report First Quarter 2027 Results and Provide a Business Update on October 9, 2026
Published on 09/24/2026 at 20:29, 3 hours 26 minutes ago EQS-Adhoc: HelloFresh SE expects revenue for Q3 2026 below market expectations and adjusts outlook for the financial year 2026
Published on 09/24/2026 at 19:00, 4 hours 55 minutes ago HIAG provides a first-hand insight into its strategy and the added value it generates at its Capital Market Day
Published on 09/24/2026 at 18:40, 5 hours 15 minutes ago EQS-Adhoc: Brockhaus Technologies AG launches public share buyback offer of approx. €90 million for up to 3,592,000 shares
Published on 09/24/2026 at 18:15, 5 hours 40 minutes ago Epanko Value Engineering Identifies 20% Production Increase
Published on 09/24/2026 at 18:05, 5 hours 50 minutes ago DCK Tools Showcases Expanded Outdoor Power Equipment Lineup at Salonvert 2026
Published on 09/24/2026 at 18:00, 5 hours 55 minutes ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 5 hours 55 minutes ago GUILLEMOT CORPORATION: 2026 CONSOLIDATED INTERIM RESULTS
Published on 09/24/2026 at 17:45, 6 hours 10 minutes ago Cegedim first-half 2026 results: profitability continues to improve
